Total submissions: 6
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Laboratory for Molecular Medicine, |
RCV000040291 | SCV000063982 | uncertain significance | not specified | 2011-12-13 | criteria provided, single submitter | clinical testing | Variant classified as Uncertain Significance - Favor Benign. The Arg13564His var iant (TTN) has not been previously reported nor previously identified by our lab oratory. Arginine (Arg) at position 13564 is not conserved in mammals and lower species, increasing the likelihood that a change may be tolerated. Computational tools are mixed on the predicted impact to the protein (AlignGVGD = benign, SIF T = pathogenic), though the accuracy of these tools is unknown. Additional infor mation is needed to fully assess the clinical significance of the Arg13564His va riant. |
Eurofins Ntd Llc |
RCV000727035 | SCV000705077 | uncertain significance | not provided | 2016-12-30 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000727035 | SCV001818701 | likely benign | not provided | 2019-04-05 | criteria provided, single submitter | clinical testing | This variant is associated with the following publications: (PMID: 24503780) |
CHEO Genetics Diagnostic Laboratory, |
RCV001798154 | SCV002042509 | uncertain significance | Cardiomyopathy | 2020-12-15 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002415481 | SCV002727091 | uncertain significance | Cardiovascular phenotype | 2020-03-27 | criteria provided, single submitter | clinical testing | The p.R7067H variant (also known as c.21200G>A), located in coding exon 85 of the TTN gene, results from a G to A substitution at nucleotide position 21200. The arginine at codon 7067 is replaced by histidine, an amino acid with highly similar properties. This amino acid position is poorly conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Revvity Omics, |
RCV000727035 | SCV003821764 | uncertain significance | not provided | 2023-09-27 | criteria provided, single submitter | clinical testing |